Work

Faculty Opinions recommendation of Second- and third-generation drugs for immuno-oncology treatment-The more the better?

Year: 2018

Type: peer-review

Source: Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

DOI: 10.3410/f.727438624.793549625

Author: Jaffer Ajani

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4250249876

Cites:

Cited by:

Related to: